Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults — NICE 2022
National clinical guideline (England) based on evidence reviews by the National Guideline Centre; covers opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. Moderate evidence. NICE guideline NG215, 20 April 2022. Free to read on the NICE website. Note: NICE found the evidence comparing tapering speeds inconclusive, so much of the advice on how to withdraw rests on committee experience; written for adults in England.
- What It Found
- NICE's guideline on withdrawing opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. Prescribers should not stop them abruptly except in exceptional circumstances such as serious side effects, should reach agreement by shared decision-making, make sure the planned rate of reduction is acceptable to the person and reviewed regularly, and explain that withdrawal can be difficult and may take several months or more. It suggests offering details of peer support.
- Why It Matters Here
- Backs up the tapering and deprescribing resources in chapter 06, especially UK ones such as Mind's coming-off-medication guide, LEAP for Prescribed Drug Dependence and the Beyond Pills Alliance, by setting out agreed, gradual withdrawal with access to peer support as recommended practice. Most relevant in the UK.
National clinical guideline (England) based on evidence reviews by the National Guideline Centre; covers opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. Moderate evidence. NICE guideline NG215, 20 April 2022. Free to read on the NICE website. Note: NICE found the evidence comparing tapering speeds inconclusive, so much of the advice on how to withdraw rests on committee experience; written for adults in England.